Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery.
The histone deacetylase inhibitors (HDACi) are potent drugs in the treatment of inflammatory diseases and defined cancer types. However, major drawbacks of HDACi, such as valproic acid (VPA), are limited serum half-life, side effects and the short circulation time. Thus, the immobilization of VPA in a polysaccharide matrix is used to circumvent these problems and to design a suitable nanocarrier system. Therefore, VPA is covalently attached to cellulose and dextran via esterification with degree of substitution (DS) values of up to 2.20. The resulting hydrophobic polymers are shaped to spherical nanoparticles (NPs) with hydrodynamic diameter between 138 to 221 nm and polydispersity indices from 0.064 to 0.094 by nanoprecipitation and emulsification technique. Lipase treatment of the NPs leads to in vitro release of VPA and hence to an inhibition of HDAC2 activity in a HDAC2 assay. NPs are rapidly taken up by HeLa cells and mainly localize in the cytoplasm. The NPs are hemocompatible and nontoxic as revealed by the shell-less hen's egg model.
['Lindemann|Henry|H|', 'Kühne|Marie|M|', 'Grune|Christian|C|', 'Warncke|Paul|P|', 'Hofmann|Susanne|S|', 'Koschella|Andreas|A|', 'Godmann|Maren|M|', 'Fischer|Dagmar|D|', 'Heinzel|Thorsten|T|', 'Heinze|Thomas|T|0000-0001-7726-6593']
D004337:Drug Carriers D057809:HEK293 Cells D006367:HeLa Cells D056464:Histone Deacetylase 2 D056572:Histone Deacetylase Inhibitors D006801:Humans D053758:Nanoparticles D011134:Polysaccharides
polysaccharides nanoparticles HDAC inhibitor valproic acid drug delivery system